Article
Oncology
Nicole Mavingire, Petreena Campbell, Jonathan Wooten, Joyce Aja, Melissa B. Davis, Andrea Loaiza-Perez, Eileen Brantley
Summary: Breast cancer stem cells (BCSCs) play a role in promoting endocrine therapy resistance through signaling cascades such as Notch, HIF, and integrin/Akt. Understanding these mechanisms can potentially lead to targeted therapy strategies to counteract endocrine resistance in HR positive breast cancer patients. Additionally, exploring the link between BCSC-regulatory gene levels and reduced survival in African American women with basal-like breast cancer may provide insights for improving clinical outcomes in this population.
Review
Endocrinology & Metabolism
Esmael Besufikad Belachew, Dareskedar Tsehay Sewasew
Summary: The estrogen receptor is crucial in the treatment of estrogen receptor-positive breast cancer, with endocrine resistance posing a challenge. Combining drugs that target different signaling pathways and coregulatory proteins with endocrine therapy may offer a novel therapeutic approach to combat endocrine resistance.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Review
Pharmacology & Pharmacy
Chao Dong, Jiao Wu, Yin Chen, Jianyun Nie, Ceshi Chen
Summary: Hyperactivation of the PI3K/AKT/mTOR pathway is associated with drug resistance and cancer progression in breast cancer patients. Current research is focusing on developing drugs targeting this pathway to overcome acquired resistance to standard therapies.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Multidisciplinary Sciences
Aditya Bardia, Sarat Chandarlapaty, Hannah M. Linden, Gary A. Ulaner, Alice Gosselin, Sylvaine Cartot-Cotton, Patrick Cohen, Severine Doroumian, Gautier Paux, Marina Celanovic, Vasiliki Pelekanou, Jeffrey E. Ming, Nils Ternes, Monsif Bouaboula, Joon Sang Lee, Anne-Laure Bauchet, Mario Campone
Summary: The study evaluates the safety and antitumor activity of amcenestrant as monotherapy in postmenopausal women with ER+/HER2- advanced breast cancer. The results show that amcenestrant is well-tolerated and demonstrates preliminary antitumor activity, suggesting its potential clinical utility.
NATURE COMMUNICATIONS
(2022)
Article
Biochemistry & Molecular Biology
Kristie H. Lau, Alexandra M. Tan, Yihui Shi
Summary: This article discusses the incidence and classification of breast cancer in the United States, and explores the main treatment methods, including surgery, radiation therapy, chemotherapy, endocrine therapy, and targeted therapy. It also highlights the research focus on triple-negative breast cancer treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Genetics & Heredity
Ozge Saatci, Kim-Tuyen Huynh-Dam, Ozgur Sahin
Summary: Endocrine resistance in ER + breast cancer involves diverse mechanisms affecting signaling pathways and cellular processes. Current clinical strategies include inhibitors targeting various key molecules to improve treatment outcomes.
JOURNAL OF MOLECULAR MEDICINE-JMM
(2021)
Review
Oncology
Covadonga Marti, Jose Ignacio Sanchez-Mendez
Summary: Treatment of breast cancer has evolved towards individualized management, with hormone therapy playing a key role. Neoadjuvant endocrine therapy has become an effective approach for many hormone receptor-positive breast cancers.
Article
Medicine, General & Internal
Matteo Lambertini, Eva Blondeaux, Giancarlo Bisagni, Silvia Mura, Sabino De Placido, Michelino De Laurentiis, Alessandra Fabi, Anita Rimanti, Andrea Michelotti, Mauro Mansutti, Antonio Russo, Filippo Montemurro, Antonio Frassoldati, Antonio Durando, Stefania Gori, Anna Turletti, Stefano Tamberi, Ylenia Urracci, Piero Fregatti, Maria Grazia Razeti, Roberta Caputo, Carmine De Angelis, Valeria Sanna, Elisa Gasparini, Elisa Agostinetto, Evandro de Azambuja, Francesca Poggio, Luca Boni, Lucia Del Mastro
Summary: This study provides evidence on the prognostic and clinical impact of the currently adopted endocrine resistance/sensitivity classification in patients with hormone receptor-positive/HER2-negative advanced breast cancer. This classification can be considered as a valid tool to guide clinical decision-making and design future treatment trials in the metastatic setting.
Article
Endocrinology & Metabolism
Ines Barone, Amanda Caruso, Luca Gelsomino, Cinzia Giordano, Daniela Bonofiglio, Stefania Catalano, Sebastiano Ando
Summary: The incidence of obesity has risen dramatically worldwide, impacting various diseases including breast cancer. Conventional endocrine therapies have limited efficacy in obese patients, and understanding the mechanisms behind obesity and endocrine therapy resistance poses a complex challenge for research. Exploring new precision medicine-based therapeutic interventions is crucial in treating obese patients with breast tumors resistant to endocrine therapies.
Article
Biochemistry & Molecular Biology
Jiefeng Huang, Jie Li, Jun Tang, Yushen Wu, Fengsheng Dai, Ziying Yi, Yan Wang, Yunhai Li, Yue Wu, Guosheng Ren, Tingxiu Xiang
Summary: This article reveals the important role of ZDHHC22 in breast cancer and its correlation with patient prognosis. ZDHHC22 inhibits the proliferation of breast cancer cells by regulating protein stability and signaling pathway activation. It has the potential to serve as a therapeutic target for endocrine therapy-resistant breast cancer patients.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2022)
Article
Oncology
Bora Lim, David A. Potter, Mohamad A. Salkeni, Paula Silverman, Tufia C. Haddad, Frederic Forget, Ahmad Awada, Jean-Luc Canon, Michael Danso, Alain Lortholary, Hugues Bourgeois, Elizabeth Tan-Chiu, Sylvie Vincent, Brittany Bahamon, Kevin J. Galinsky, Chirag Patel, Rachel Neuwirth, E. Jane Leonard, Jennifer R. Diamond
Summary: The study evaluated the efficacy and safety of sapanisertib plus exemestane or fulvestrant in treating advanced/metastatic hormone receptor-positive breast cancer, showing certain clinical benefit for patients. The treatment demonstrated different efficacy in patients previously sensitive or resistant to exemestane.
CLINICAL CANCER RESEARCH
(2021)
Editorial Material
Oncology
Niamh C. Cunningham, Nicholas C. Turner
Summary: CDK4/6 inhibitors have shown consistent efficacy in the treatment of metastatic breast cancer, but recent adjuvant trials for early stage breast cancer have produced conflicting results, highlighting the need for further research on their clinical utility and future trial design.
Review
Oncology
Michela Roberto, Antonio Astone, Andrea Botticelli, Luisa Carbognin, Alessandra Cassano, Giuliana D'Auria, Agnese Fabbri, Alessandra Fabi, Teresa Gamucci, Eriseld Krasniqi, Mauro Minelli, Armando Orlandi, Francesco Pantano, Ida Paris, Laura Pizzuti, Ilaria Portarena, Nello Salesi, Simone Scagnoli, Paola Scavina, Giuseppe Tonini, Patrizia Vici, Paolo Marchetti
Summary: The addition of CDK4-6 inhibitors has significantly improved the outcomes of patients with HR+ advanced breast cancer, but further research is needed to determine the optimal selection criteria and predictive biomarkers for these drugs.
Article
Multidisciplinary Sciences
Rena Emond, Jason I. Griffiths, Vince Kornel Grolmusz, Aritro Nath, Jinfeng Chen, Eric F. Medina, Rachel S. Sousa, Timothy Synold, Frederick R. Adler, Andrea H. Bild
Summary: The interplay between drug-sensitive and resistant cells has an impact on the effectiveness of treatment in cancer cell populations. In this study, interaction between estrogen receptor-positive breast cancer cell lineages that are sensitive and resistant to CDK4/6 inhibition was explored. It was found that resistant cells facilitate the growth of sensitive cells through increased metabolism and estradiol production.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Alexandra Thomas, Heather A. Parsons, Karen Lisa Smith
Summary: The Oncology Grand Rounds series aims to integrate research reports with clinical practice, helping readers better understand how to apply research findings to patient treatments.
JOURNAL OF CLINICAL ONCOLOGY
(2022)